Sodium MRI of the Hip

髋关节钠 MRI

基本信息

批准号：
8897271
负责人：
Guillaume MADELIN
金额：
$ 8.48万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-08-01 至 2017-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8897271
关键词：
Affect American Arthritis Biochemical Biochemical Markers Cartilage Chemicals Chronic Clinical Coiled Bodies Collagen Fiber Complement Concentration measurement Cone Data Degenerative Disorder Degenerative polyarthritis Detection Development Diagnosis Diagnostic Imaging Diffusion Diffusion Magnetic Resonance Imaging Disadvantaged Disease Disease Progression Early Diagnosis Elderly Etiology Future Gadolinium Geometry Glycosaminoglycans Goals Gold Grant Health Heterogeneity Hip Joint Hip Osteoarthritis Hip Pain Hip region structure Image Imaging Techniques Individual Joints Liquid substance Magnetic Resonance Imaging Maps Measurement Measures Methods Noise Nuclear Magnetic Resonance Pain management Patients Performance Pharmaceutical Preparations Physiologic pulse Pilot Projects Population Prevalence Protons Publishing Radial Recovery Relaxation Replacement Arthroplasty Research Resolution Risk Scanning Sensitivity and Specificity Signal Transduction Sodium Sodium Channel Speed Synovial Fluid Techniques Time Tissues Water articular cartilage base cartilage degradation data acquisition disability follow-up gadolinium oxide healthy volunteer high risk imaging modality improved in vivo magnetic field novel radiofrequency reconstruction

项目摘要

DESCRIPTION (provided by applicant): Osteoarthritis (OA) is the most common form of arthritis in synovial joints and a leading cause of chronic disability, mainly in the elderly population. It currently affects 9% of the US population and is expected to affect 19% of Americans by 2030. OA is a degenerative disease of articular cartilage and is mainly characterized by a loss of glycosaminoglycans (GAG), change in size and organization of collagen fibers, and increased water content. There is no known cure for OA and present treatments focus mainly on pain management and ultimately, joint replacement. There are many obstacles to studying OA (heterogeneity in etiology, variability in progression of disease, long time periods required to see morphological joint changes), and consequently we currently lack the ability to predict the course of the disease. The limitation of identifying OA patients at riskfor progression and the lack of available non-invasive early biochemical markers have impeded the clinical development of potential disease modifying OA drugs (DMOAD). Specifically, hip osteoarthritis has a prevalence from 3 to 11% in Western population over 35 years old, and it is the main cause of hip pain in older adults. Quantitative sodium magnetic resonance imaging (MRI) is a non-invasive technique that is highly specific to the GAG content in cartilage that could be used to assess the degree of biochemical degradation of cartilage in OA. However, due to the low sodium concentration in vivo, its low sensitivity and fast relaxation, detecting the sodium signal in cartilage requires high fields (>3T), specific coils and specific 3D non-Cartesian sequences with ultrashort echo time. To the best of our knowledge, no study on sodium MRI of the hip was published to date. The recent acquisition of a dual-tuned body coil for imaging at 3T by our research team will allow us to acquire co-registered proton and sodium images of the hip within the same session. Quantitative sodium MRI could therefore provide a unique endogenous assessment of cartilage GAG content in clinically feasible scan times (20-25 min), and allow detection of OA in articular cartilage before morphological damage occurs and help assessing the effect of DMOAD treatments. The aims of this pilot study are: 1) to develop and optimize the acquisition and reconstruction of quantitative sodium MRI of the hip joint in vivo (to optimize the acquisition sequence parameters for minimizing the acquisition time, increasing the signal-to-noise ratio and spatial resolution, to measure relaxation times and B1 maps, and to optimize synovial fluid suppression) and, 2) to apply quantitative sodium MRI to subjects with and without hip OA (to assess repeatability, sensitivity, specificity of the method, with and without fluid suppression). This method could profoundly affect how we diagnose OA in the hip joint and may allow the identification of high risk individuals and also assess DMOAD treatment follow-ups. Successful completion of this pilot project would allow us to apply to a R01 grant for improving the speed of sodium data acquisition (using compressed sensing) and investigating the clinical value of quantitative sodium MRI for assessing different degrees of OA in comparison to other proton-based imaging techniques such as dGEMRIC, T1 mapping or diffusion imaging.

描述（由申请人提供）：骨关节炎（OA）是滑膜关节中最常见的关节炎形式，也是慢性残疾的主要原因，主要发生在老年人群中。目前它影响着 9% 的美国人口，预计到 2030 年将影响 19% 的美国人。 OA 是一种关节软骨退行性疾病，主要特征是糖胺聚糖 (GAG) 损失、胶原纤维大小和组织变化，并增加含水量。骨关节炎尚无已知的治愈方法，目前的治疗主要集中在疼痛管理和最终的关节置换上。研究 OA 存在许多障碍（病因的异质性、疾病进展的变异性、观察关节形态变化需要很长时间），因此我们目前缺乏预测疾病进程的能力。识别有进展风险的 OA 患者的局限性以及缺乏可用的非侵入性早期生化标志物阻碍了潜在的疾病缓解 OA 药物 (DMOAD) 的临床开发。具体来说，髋骨关节炎在35岁以上的西方人群中患病率为3%至11%，是老年人髋部疼痛的主要原因。定量钠磁共振成像 (MRI) 是一种非侵入性技术，对软骨中的 GAG 含量具有高度特异性，可用于评估 OA 中软骨的生化降解程度。但由于体内钠浓度低，其灵敏度低、弛豫快，检测软骨中的钠信号需要高场 (>3T)、特定线圈和特定 3D 非笛卡尔具有超短回波时间的序列。据我们所知，迄今为止尚未发表有关髋关节钠 MRI 的研究。我们的研究团队最近获得了用于 3T 成像的双调谐身体线圈，这将使我们能够在同一会话中获得臀部的共同配准质子和钠图像。因此，定量钠 MRI 可以在临床可行的扫描时间（20-25 分钟）内对软骨 GAG 含量进行独特的内源性评估，并允许在形态损伤发生之前检测关节软骨中的 OA，并帮助评估 DMOAD 治疗的效果。本试点研究的目的是：1）开发和优化体内髋关节定量钠 MRI 的采集和重建（以优化采集序列参数，用于最大限度地缩短采集时间，提高信噪比和空间分辨率，测量弛豫时间和 B1 图，并优化滑液抑制），2）对患有和不患有这种疾病的受试者应用定量钠 MRI髋关节 OA（评估方法的重复性、敏感性、特异性，有或没有液体抑制）。这种方法可能会深刻影响我们诊断髋关节 OA 的方式，并可能识别高风险个体并评估 DMOAD 治疗随访。该试点项目的成功完成将使我们能够申请 R01 拨款，以提高钠数据采集速度（使用压缩传感），并研究定量钠 MRI 与其他基于质子的 MRI 相比评估不同程度 OA 的临床价值成像技术，例如 dGEMRIC、T1 映射或扩散成像。